Pfizer Inc. (NYSE:PFE) is one of Goldman Sachs top healthcare stocks. On March 9, analysts at BMO reiterated an Outperform ...
Pfizer (NYSE:PFE) has started a Phase 1 trial of a new tafamidis tablet formulation aimed at improving manufacturing flexibility and cost-efficiency. The company has initiated a Phase 2 pediatric ...
Is PFE a good stock to buy now? We came across a bullish thesis on Pfizer Inc. on Investomine’s Substack. In this article, we will summarize the bulls’ thesis on PFE. Pfizer Inc.’s share was trading ...
Zacks Investment Research on MSN
Pfizer Inc. (PFE) is a trending stock: Facts to know before betting on it
Pfizer (PFE) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term. Shares of this ...
Pfizer (PFE) looks undervalued at 8–9x forward earnings with a ~7% yield; see how Seagen, cost cuts and the pipeline could drive $36–42 upside—read now.
The reason is so compelling that I actually did buy the stock -- and I have no plans to sell.
Pfizer ( PFE) said its Phase 2 study of tilrekimig (PF-07275315), a trispecific antibody for atopic dermatitis, showed positive results.
The general mood among these heavyweight investors is divided, with 44% leaning bullish and 55% bearish. Among these notable options, 6 are puts, totaling $448,868, and 3 are calls, amounting to ...
Pfizer Inc. (NYSE:PFE) is one of the best cheap stocks under $50 to buy right now. Pfizer Inc. (NYSE:PFE) and Astellas Pharma ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results